Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.

Breslow thickness malignant melanoma prognosis risk factors ulceration vitamin D

Journal

Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990

Informations de publication

Date de publication:
2020
Historique:
accepted: 24 09 2019
entrez: 11 1 2020
pubmed: 11 1 2020
medline: 11 1 2020
Statut: epublish

Résumé

Recent data have shown an inverse association between serum 25-hydroxyvitamin D concentration and incidence of several cancers, including cutaneous malignant melanoma (CMM). In addition, lower serum 25-hydroxyvitamin D levels have been associated with thicker or higher stage melanomas and worse survival in observational studies. Ninety-nine patients diagnosed with primary CMM and 97 matched healthy controls entered the study. Demographic characteristics, risk factors for CMM, and clinical and histological characteristics were recorded for patients with primary CMM. Total serum 25-hydroxyvitamin D levels of melanoma patients measured by fully automated chemiluminescent vitamin D total immunoassay (Elecsys vitamin D total, Roche) at the time of diagnosis were compared with those of healthy controls. In addition, we tested the association of serum total 25-hydroxyvitamin D levels at melanoma diagnosis with known risk and prognostic factors for CMM. Of the melanoma patients, 49 (49.49%) had deficient serum total 25-hydroxyvitamin D levels (<20 ng/mL), 23 (23.23%) had insufficient levels (21-29 ng/mL), and 27 (27.27%) had adequate levels (>30 ng/mL). The median serum total 25-hydroxyvitamin D levels were significantly lower in melanoma patients (20.62 ng/mL) compared with healthy controls (24.71 ng/mL), but statistical significance was not reached (chi-square test, P = 0.051) No statistically significant association was found between serum total 25-hydroxyvitamin D levels and demographic characteristics; risk factors for CMM; prognostic factors, such as Breslow thickness and ulceration; as well as clinical characteristics, such as melanoma stage, clinical type, and location. Lower serum 25-hydroxyvitamin D levels were found in our Greek cohort of melanoma patients compared with healthy controls, without reaching, however, statistical significance; these levels were not statistically associated with established risk and prognostic factors for CMM.

Sections du résumé

BACKGROUND BACKGROUND
Recent data have shown an inverse association between serum 25-hydroxyvitamin D concentration and incidence of several cancers, including cutaneous malignant melanoma (CMM). In addition, lower serum 25-hydroxyvitamin D levels have been associated with thicker or higher stage melanomas and worse survival in observational studies.
MATERIALS AND METHODS METHODS
Ninety-nine patients diagnosed with primary CMM and 97 matched healthy controls entered the study. Demographic characteristics, risk factors for CMM, and clinical and histological characteristics were recorded for patients with primary CMM. Total serum 25-hydroxyvitamin D levels of melanoma patients measured by fully automated chemiluminescent vitamin D total immunoassay (Elecsys vitamin D total, Roche) at the time of diagnosis were compared with those of healthy controls. In addition, we tested the association of serum total 25-hydroxyvitamin D levels at melanoma diagnosis with known risk and prognostic factors for CMM.
RESULTS RESULTS
Of the melanoma patients, 49 (49.49%) had deficient serum total 25-hydroxyvitamin D levels (<20 ng/mL), 23 (23.23%) had insufficient levels (21-29 ng/mL), and 27 (27.27%) had adequate levels (>30 ng/mL). The median serum total 25-hydroxyvitamin D levels were significantly lower in melanoma patients (20.62 ng/mL) compared with healthy controls (24.71 ng/mL), but statistical significance was not reached (chi-square test, P = 0.051) No statistically significant association was found between serum total 25-hydroxyvitamin D levels and demographic characteristics; risk factors for CMM; prognostic factors, such as Breslow thickness and ulceration; as well as clinical characteristics, such as melanoma stage, clinical type, and location.
CONCLUSIONS CONCLUSIONS
Lower serum 25-hydroxyvitamin D levels were found in our Greek cohort of melanoma patients compared with healthy controls, without reaching, however, statistical significance; these levels were not statistically associated with established risk and prognostic factors for CMM.

Identifiants

DOI: 10.5826/dpc.1001a10 PMID: 31921497 PMC: PMC6936640
pubmed: 31921497
doi: 10.5826/dpc.1001a10
pii: dp1001a10
pmc: PMC6936640
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e2020010

Informations de copyright

Copyright: ©2019 Befon et al.

Déclaration de conflit d'intérêts

Competing interests: The authors have no conflicts of interest to disclose.

Références

Hormones (Athens). 2016 Apr;15(2):205-223
pubmed: 27376424
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Br J Dermatol. 2013 Mar;168(3):625-8
pubmed: 22880705
PLoS One. 2015 May 13;10(5):e0126394
pubmed: 25970336
J Epidemiol. 2018 Jan 5;28(1):27-33
pubmed: 29176271
Eur J Cancer Prev. 2017 Nov;26(6):532-541
pubmed: 28125434
PLoS One. 2014 Dec 01;9(12):e112863
pubmed: 25437008
Endocrinology. 2000 Nov;141(11):3931-9
pubmed: 11089522
J Investig Med. 2011 Aug;59(6):881-6
pubmed: 21527855
Br J Nutr. 2017 Oct;118(7):550-558
pubmed: 28965512
Einstein (Sao Paulo). 2014 Oct-Dec;12(4):473-6
pubmed: 25628199
J Clin Oncol. 2016 May 20;34(15):1713-4
pubmed: 27044934
Int J Oncol. 2000 Jun;16(6):1249-54
pubmed: 10812003
Australas J Dermatol. 2018 Aug;59(3):182-187
pubmed: 28332194
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):671-80
pubmed: 21872807
Medicine (Baltimore). 2018 Mar;97(13):e0114
pubmed: 29595633
Lancet. 1995 Jul 22;346(8969):207-10
pubmed: 7616799
Joint Bone Spine. 2010 Dec;77(6):552-7
pubmed: 21067953
Br J Dermatol. 2006 Jun;154(6):1123-7
pubmed: 16704644
Carcinogenesis. 2016 Jan;37(1):30-8
pubmed: 26521212
J Clin Endocrinol Metab. 2007 Jun;92(6):2130-5
pubmed: 17426097
Breast Cancer (Auckl). 2017 Dec 20;11:1178223417749816
pubmed: 29434472
Ann Epidemiol. 2009 Jul;19(7):455-61
pubmed: 19282200
Int J Cancer. 2015 Jun 15;136(12):2890-9
pubmed: 25403087
Anticancer Res. 2018 Feb;38(2):1145-1151
pubmed: 29374751
Cancer Biol Ther. 2007 Jan;6(1):48-55
pubmed: 17172823
Acta Derm Venereol. 2011 Mar;91(2):115-24
pubmed: 21384086
Int J Mol Sci. 2016 Jan 08;17(1):null
pubmed: 26760999
Eur J Cancer. 2014 Oct;50(15):2649-58
pubmed: 25087185
Front Public Health. 2016 Apr 28;4:78
pubmed: 27200331
J Clin Oncol. 2016 May 20;34(15):1741-7
pubmed: 27001565
Anticancer Res. 2009 Sep;29(9):3669-74
pubmed: 19667163
J Am Acad Dermatol. 2017 Sep;77(3):575-577
pubmed: 28807113
J Natl Cancer Inst. 2015 Sep 15;107(12):djv264
pubmed: 26376687
J Clin Oncol. 2009 Nov 10;27(32):5439-44
pubmed: 19770375
Eur J Cancer Prev. 2019 May;28(3):203-211
pubmed: 29438161
Ann N Y Acad Sci. 2001 Dec;952:73-87
pubmed: 11795445
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1758-65
pubmed: 26364161

Auteurs

Angeliki Befon (A)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Alexander C Katoulis (AC)

Second Department of Dermatology and Venereology, Attikon General University Hospital, National and Kapodistrian University of Athens, Greece.

Sofia Georgala (S)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Andreas Katsampas (A)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Vasiliki Chardalia (V)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Aggeliki Melpidou (A)

Biochemistry Laboratory, Evangelismos General Hospital of Athens, Greece.

Vasiliki Tzanetakou (V)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Vasiliki Chasapi (V)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Dorothea Polydorou (D)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Clio Desinioti (C)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Micaela Plaka (M)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Dimitris Rigopoulos (D)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Alexandros J Stratigos (AJ)

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Andreas Syggros Hospital for Skin and Venereal Diseases, Athens, Greece.

Classifications MeSH